Cargando…

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

INTRODUCTION: There have been several important developments in antiretroviral treatment in the past two years. Randomized clinical trials have been conducted to evaluate a lower dose of efavirenz (400 mg once daily). Integrase inhibitors such as dolutegravir have been approved for first-line treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitoria, Marco, Hill, Andrew M, Ford, Nathan P, Doherty, Meg, Khoo, Saye H, Pozniak, Anton L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740352/ https://www.ncbi.nlm.nih.gov/pubmed/26842728 http://dx.doi.org/10.7448/IAS.19.1.20504

Ejemplares similares

Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All
por: Ford, Nathan, et al.
Publicado: (2018)

For children left behind, we need to know more and do more
por: The Lancet Regional Health – Western Pacific
Publicado: (2023)

When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank
por: Vitoria, Marco, et al.
Publicado: (2017)

Carcinogenesis: The more we seek to know the more we need to know – Challenges in the post Genomic Era
por: Kovvali, Gopala, et al.
Publicado: (2003)

Plant virus metagenomics: what we know and why we need to know more
por: Stobbe, Anthony H., et al.
Publicado: (2014)

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment
por: Ford, Nathan, et al.
Publicado: (2020)

Commentary: We need to know more about erythropoietin
por: D'Ambra, Michael N.
Publicado: (2020)

We Need More Continuity Training
por: Doolittle, Benjamin R
Publicado: (2022)

COVID-19—What we know and what we need to know: There are more questions than answers
por: Maisch, Bernhard, et al.
Publicado: (2020)

Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)

WHO guidance to support HIV care models during the Covid-19 era
por: Ford, Nathan, et al.
Publicado: (2021)

Membrane fission by dynamin: what we know and what we need to know
por: Antonny, Bruno, et al.
Publicado: (2016)

Micronutrients and the Immune System: Some Is Good but We Need to Know More
por: Thompson, Henry J.
Publicado: (2021)

Benefits and risks of rapid initiation of antiretroviral therapy
por: Ford, Nathan, et al.
Publicado: (2018)

Big Tau: What We Know, and We Need to Know
por: Fischer, Itzhak
Publicado: (2023)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

Publication ethics – What do we need to know?
por: Mills, Michael
Publicado: (2019)

We Need to Know … Now!
por: Wojtys, Edward M.
Publicado: (2012)

Epigenetics in Schistosomes: What We Know and What We Need Know
por: Liu, Weiwei
Publicado: (2016)

Portion Size: What We Know and What We Need to Know
por: Benton, David
Publicado: (2015)

Paediatric schistosomiasis: What we know and what we need to know
por: Osakunor, Derick N. M., et al.
Publicado: (2018)

Metabolic syndrome: what we know and what we need to know
por: Soares, Raquel
Publicado: (2020)

Q&A: Antibiotic resistance: what more do we know and what more can we do?
por: Wright, Gerard D
Publicado: (2013)

Histamine Intolerance—The More We Know the Less We Know. A Review
por: Hrubisko, Martin, et al.
Publicado: (2021)

Getting to zero HIV deaths: progress, challenges and ways forward
por: Ford, Nathan, et al.
Publicado: (2013)

Cardiac surgery and the coronavirus disease 2019 pandemic: What we know, what we do not know, and what we need to do
por: Bakaeen, Faisal G., et al.
Publicado: (2020)

Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?
por: Shapter, Frances Marie, et al.
Publicado: (2023)

In a search of a protective titer: Do we or do we not need to know?
por: Baranova, Ancha, et al.
Publicado: (2021)

Veteran homelessness in Australia: What do we know? What has been done? What do we need to do?
por: Wallace, Duncan, et al.
Publicado: (2023)

COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
por: Dhawan, Rahul, et al.
Publicado: (2020)

Nephrotoxicity testing in vitro--what we know and what we need to know.
por: Pfaller, W, et al.
Publicado: (1998)

Goal-directed therapy: what we know and what we need to know
por: O’Neal, Jason B, et al.
Publicado: (2015)

Microplastics in freshwater ecosystems: what we know and what we need to know
por: Wagner, Martin, et al.
Publicado: (2014)

Peri-implant disease: what we know and what we need to know
por: Valente, Nicola Alberto, et al.
Publicado: (2016)

Olfaction and COVID: The little we Know and what else we need to know
por: Pinna, Fábio de Rezende, et al.
Publicado: (2020)

Pneumonia in Bhutanese children: what we know, and what we need to know
por: Jullien, Sophie, et al.
Publicado: (2020)

Impacts of Neonicotinoids on Molluscs: What We Know and What We Need to Know
por: Ewere, Endurance E, et al.
Publicado: (2021)

Pregnant adolescents living with HIV: what we know, what we need to know, where we need to go
por: Callahan, Tegan, et al.
Publicado: (2017)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_q6foqif78fac8ad8ssrsf1m4if